Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sunvozertinib as Neoadjuvant and Adjuvant Therapy in Stage II-IIIB Non-small-cell Lung Cancer Patients With EGFR Exon 20 Insertion Mutation: a Single-arm, Phase 2 Study (WU-KONG20)

NCT06864624 is registered in ClinicalTrials.gov with Tang-Du Hospital as lead sponsor.

NCT NCT06864624
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06864624 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sunvozertinib as Neoadjuvant and Adjuvant Therapy in Stage II-IIIB Non-small-cell Lung Cancer Patients With EGFR Exon 20 Insertion Mutation: a Single-arm, Phase 2 Study (WU-KONG20)
Lead sponsor
Tang-Du Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
February 18, 2025
Completion date
June 30, 2029
Enrollment
27 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc